Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma
3 clinical trials · Condition
◉ Watch Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma
| Record | Firm | Date |
|---|---|---|
| Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma (NCT03422536) | University of Arizona | 2017-12-05 |
| Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy (NCT01256385) | National Cancer Institute (NCI) | 2010-11-01 |
| Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer (NCT00458978) | National Cancer Institute (NCI) | 2007-02-01 |
Track Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.